Clifford Chance advises CBC Group and Mubadala on the acquisition of UCB's mature business (neurology and allergy) in China

en
zh
Language options

27 September 2024

Yi Yang, Maggie Lo, Fang Bao, Carolin Kemmner, Dayu Man, Cynthia Mo, Haaike Wouters, Annabel Joschko, Jia Yin Leong
Shanghai, Brussels, Düsseldorf, Hong Kong

Clifford Chance advises CBC Group and Mubadala on the acquisition of UCB's mature business (neurology and allergy) in China

Global law firm Clifford Chance has acted as international legal counsel and advised CBC Group, Asia's largest healthcare-dedicated asset management firm and Mubadala, an investment company headquartered in Abu Dhabi, in signing a strategic transaction with UCB, a global biopharmaceutical company based in Belgium. The transaction involves the sale, divestment and license of UCB's mature business (neurology and allergy) in China, including Keppra®, Vimpat®, Neupro®, Zyrtec®, Xyzal® as well as UCB’s Zhuhai manufacturing site, to CBC Group and Mubadala, for an amount of US$680 million.

The transaction is subject to certain closing conditions, including required anti-trust clearance(s) and other customary conditions, and is expected to close in Q4 2024.

Shanghai partner Yang Yi said, "We are honoured to have supported CBC Group and Mubadala in this strategic acquisition. It again demonstrates the strength and depth of our cross-border capabilities, and underscores our ability to deliver comprehensive legal solutions across multiple jurisdictions."

Yi led a cross-border team of lawyers in China, Belgium and Germany. The team comprised partner Maggie Lo, counsel Bao Fang, Carolin Kemmner and Dayu Man, senior associate Cynthia Mo, associates Haaike Wouters, Annabel Joschko, and Jia Yin Leong and trainee Ashley Tan. Zhong Lun Law Firm acted as PRC local counsel to CBC and Mubadala.

Clifford Chance has a track record of advising on landmark and innovative transactions in the healthcare and life sciences sector including advising on Keymed Biosciences' out-licensing transaction with Belenos Biosciences, Sciclone Pharmaceuticals HK$8.79 billion privatisation by GL Capital, Haier Group on the global regulatory filings for its acquisition of a 20% equity stake in blood products company Shanghai RAAS from Grifols and medical devices company MicroPort Scientific Corporation on its convertible loan facility and credit support.

高伟绅律师事务所为康桥资本与穆巴达拉收购优时比在中国的成熟产品业务（神经系统和抗过敏产品）提供法律服务

全球领先的律师事务所高伟绅近期作为康桥资本(CBC Group)（亚洲最大医疗保健资产管理集团）和穆巴达拉(Mubadala)（总部位于阿布扎比的全球投资机构）的国际法律顾问，就其与优时比(UCB)（总部位于比利时的全球生物制药公司）签订战略交易提供法律服务。
交易涉及优时比以6.8亿美元的价格向康桥资本和穆巴达拉出售其在中国的成熟产品业务（神经系统和抗过敏产品），包括 Keppra®、Vimpat®、Neupro®、Zyrtec®、Xyzal®以及优时比在珠海的生产基地。

此次交易尚需满足包括反垄断审批等在内的多项交割条件和其他惯例条件，预计将于2024年第四季度完成。

高伟绅上海办事处合伙人杨毅律师表示：我们非常荣幸能在此次战略收购交易中为康桥资本和穆巴达拉提供法律支持。这再次证明我们提供跨司法辖区全面法律解决方案的能力。

高伟绅此次交易的跨境法律服务团队由合伙人杨毅和劳凯欣牵头。核心团队成员包括包昉、Carolin Kemmner、满大宇、毛心欣、Haaike Wouters、Annabel Joschko、梁嘉茵、谈妍霏等。中伦律师事务所任康桥资本和穆巴达拉在此次交易中的中国法律顾问。

高伟绅在为医疗保健和生命科学领域具有里程碑意义的创新交易提供法律服务方面拥有良好往绩，包括就康诺亚生物医药与Belenos Biosciences订立许可协议提供法律服务；就德福资本(GL Capital)以87.9亿港元对塞生药业(Spiclone Pharmaceuticals)的私有化交易，为塞生药业提供法律服务；就海尔集团向基立福(Grifols)收购血液制品公司上海莱士20%股权所涉全球监管备案提供法律服务；就医疗器械公司微创医疗科学有限公司的可换股贷款融资和信贷支持等提供法律服务。